http:https://www.congressweb.com/AssociationMP Sat, 04 Apr 2026 09:41:32 GMT http:https://www.congressweb.com/AssociationMP/21 <div>Urge Congress to support the RESULTS Act&nbsp;Now!</div> <div>&nbsp;</div> <div>The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (H.R. 5269 / S. 2761), introduced on September 10^th, 2025, is a sustainable, long-term solution to the issues caused by the Protecting Access to Medicare Act &nbsp;of 2014 (PAMA). When PAMA was implemented, the Clinical Laboratory Fee Schedule (CLFS) rates were set based on data collected from less than one percent of all laboratories, resulting in artificially low payment rates. As a result of this implementation, <strong>over 800 laboratory tests on the CLFS will be cut –up to 15% per test—on January 1, 2026.</strong></div> <div>&nbsp;</div> <div>The RESULTS Act would provide long-term payment reform while protecting access to laboratory tests through a streamlined approach that would stabilize reimbursement for clinical laboratory services essential for patients and public health.</div> <div>&nbsp;</div> <div>Write your legislator today to support&nbsp;the RESULTS Act as an alternative solution to Medicare cuts!&nbsp;</div> Mon, 01 Dec 2025 05:00:00 GMT http:https://www.congressweb.com/AssociationMP/21 http:https://www.congressweb.com/AssociationMP/20 <div>On May 1^st 2025, Senator Thom Tillis (R-NC), Senator Chris Coons (D-DE), Representative Kevin Kiley (R-CA) and Representative Scott Peters (D-CA) reintroduced the Patent Eligibility Restoration Act (“PERA”). This extreme legislation would overturn 150 years of Supreme Court precedent and allow patents on laws of nature, products of nature, and abstract ideas. For healthcare, this would be a radical upheaval that would threaten the significant progress made in precision medicine, reduce patient access to lifesaving genetic tests, and slow medical innovation. The bill would also create testing bottlenecks during public health emergencies. If enacted, essentially this would mean that a single patent holder could control all research and clinical evaluation associated with a biomarker, such as a genetic variant, and create a monopoly in which they are the only testing provider.</div> <div>&nbsp;</div> <div>Tell your members of Congress to oppose S.1546 / H.R. 3152: the Patent Eligibility Restoration Act and protect patient access to life-saving innovation.</div> Mon, 05 May 2025 04:00:00 GMT http:https://www.congressweb.com/AssociationMP/20